GSK, CureVac Expand Licensing Agreement: GSK will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or mRNA, candidate vaccines for influenza and Covid-19.
SOURCES
Mastodon3
Bluesky1
Mastodon3Bluesky1News2
- Jul 3 did:plc:pdtz3yegxbpzc5pauuhms3wwBritish Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccine candidates from CureVac, for diseases including Covid, seasonal flu and avian flu.
- Forbes• Robert Hart, Fo...GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
- @Grafa@mastodon.socialGSK (NYSE:GSK) inks licensing deal with CureVac for mRNA vaccines - published 03 Jul 2024 #NYSE#News#Partnership#Nasdaq#Payments
- @FT@press.coopGSK signs €1.4bn mRNA vaccine deal with troubled biotech CureVac New agreement hands UK drugmaker control of developing jabs and provides cash injection for German group #press
- @wsj@mstd.seungjin.netGSK, CureVac Expand Licensing Agreement: Under a new licensing deal with CureVac, GSK will acquire full rights to develop, manufacture and commercialize internationally messenger RNA, or mRNA, candidate vaccines for influenza and Covid-19. (Wed, 03 Jul 2024 03:57:00 -0400)